Sort   by:  
 Page size 
UnknownComparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.
Not available
S-EPMC12554547 | biostudies-literature
UnknownComparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Not available
S-EPMC11004131 | biostudies-literature
UnknownEradicating mesothelin-positive human gastric and pancreatic tumors in xenograft models with optimized anti-mesothelin antibody-drug conjugates from synthetic antibody libraries.
Not available
S-EPMC8322431 | biostudies-literature
UnknownComparing Low- or Standard-Dose Alteplase in Endovascular Thrombectomy: Insights From a Nationwide Registry.
Not available
S-EPMC10896194 | biostudies-literature
UnknownClinical impact of pharmacogenetic risk variants in a large chinese cohort.
Not available
S-EPMC12241563 | biostudies-literature
UnknownThe Taiwan Precision Medicine Initiative provides a cohort for large-scale studies.
Not available
S-EPMC12675286 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
Sort   by:  
 Page size